AB0232 Remission on the Basis of Self-Assessment Tools in Patients with Rheumatoid Arthritis Treated with Tocilizumab. (9th June 2015) - Starkova, A.
Abstract : Objectives: To analyze the rate of remissions in RA pts treated with tocilizumab (TCZ) on self-assessment index. Methods: The study included 42 RA pts, predominantly female, 86% were RF-positive and, 84% - ACCP-positive, mean age 50, 5±3, 1 y, mean disease duration 5, 6±4, 74 y., high disease activity was established in 93% patients. Prior to TCZ all pts were receiving DMARDs, mostly methotrexate at average dose 15, 0±2, 7 mg/week; 14, 3% pts - leflunomide 20 mg/day; 11, 9% - sulfasalazine 2 g/day for at least 3 months without any improvement. TCZ 8 mg/kg was administered every 4 weeks during 24 weeks. Treatment outcomes were assessed by patients using RAPID-3, DAS28, CDAI, SDAI. Results: Before therapy average RAPID-3 was 15, 6 [11, 5;18, 85]. After first infusion remission by RAPID-3 scale was achieved in 14% patients, at week 12 – in 20, 3%, after 16 weeks - in 25%, by week 20 – in 30, 5%, by week 24 - in 33, 3% patients. After 6 month of TCZ therapy remission or low disease activity was achieved in 61, 9% patients. Comparable results in were documented on SDAI (33%), CDAI (31%) and RAPID-3 (33, 3%) scales. By week 24 of therapy maximum percentage of remissions was registered by DAS28 (71, 4%). Conclusions: Remissions rates on RAPID-3 are similar to SDAI and CDAI, and 2-fold lower than the rates by DAS28 score. The difference in remissions rates is most likely explained by subjective factor in patient's self-assessment using RAPID-3, CDAI and SDAI scales vs physician's oversized assessment of patient's health status using DAS28 . Disclosure of Interest: None declared